Research & development services to support preclinical pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N91021D00020
- Awardee
-
Mayo Clinic UEI Y2K4F9RPRRG7 Part of Mayo Clinic
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 2 $54,971 obligated
Award facts
- Opportunity
-
- Preclinical Pharmacokinetic and Pharmacology Evaluations of Pre-Solicitation · 75N91021R00007 · Posted Mar 23, 2020
- Combined order value
-
- $54,971 Current, with exercised options
- $216,674 Potential, with all options
- Last date to order 72% complete
- IDV ceiling 1% used
- $9,900,000.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This federal Indefinite Delivery Contract (IDC) award from the National Cancer Institute (NCI) to Mayo Clinic, a renowned non-profit academic medical center, aims to obtain research and development services to support preclinical pharmacokinetic and pharmacology evaluations of cancer therapeutics being developed for clinical trials.
The base IDC contract, valued at up to $9.9 million over 7 years, does not have a set-aside designation. Under this IDIQ contract vehicle, the NCI can issue task orders to Mayo Clinic to perform a range of specialized services, including implementing and validating analytical methodologies, conducting rapid pharmacokinetic assessments, and generating data to support the drug development process from lead selection through early clinical trials. The initial $1,070 task order provides funding for contract orientation and a kick-off meeting. This work will contribute to the NCI's Experimental Therapeutics program, which aims to advance the development of new cancer-fighting agents.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N91021D00020?
75N91021D00020 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on September 27, 2021.
How much is contract 75N91021D00020 worth?
Orders under 75N91021D00020 have obligated $54,971. Their combined potential value, with all options, is $216,674. 75N91021D00020's own ceiling is $9,900,000.
How many orders have been placed under contract 75N91021D00020?
2 orders have been placed under 75N91021D00020, the latest on September 28, 2026.
Who can order from contract 75N91021D00020?
75N91021D00020 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N91021D00020 competed?
The extent of competition for 75N91021D00020 was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV